Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 276, Issue 1-2, Pages 195-201Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2014.08.623
Keywords
Progressive multiple sclerosis; Methylprednisolone; CCR2; CD38; CD80; CD70; CD27
Categories
Ask authors/readers for more resources
Objective: To investigate the effect of monthly oral methylprednisolone pulse treatment in progressive MS. Methods: 30 progressive MS patients were treated with oral methylprednisolone every month. Peripheral blood mononuclear cells were analyzed by flow cytometry. Results: Out of 102 leukocyte phenotypes investigated, 25 changed at nominal significance from baseline to week 12 (p < 0.05). After correction for multiple comparisons, we found 5 subpopulations that changed compared to baseline. No pattern were suggesting modulation of Th17 or TFH cells. Conclusion: Methylprednisolone pulse treatment has some effects on circulating immune cells but does not modulate markers of Th17 and TFH cell activity in progressive MS. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available